Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eleven Biotherapeutics (EBIO) PT Raised to $8 at Leerink Partners
August 13, 2015 2:13 PM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on Eleven Biotherapeutics (NASDAQ: EBIO) from $6 up to $8.35 following Q2 results and upside to EBI-005 phase 3 readout.
Gerberry noted that EBIO's Q2 loss of about $7 million was slightly narrower than the firm's outlook for a loss of about $8 million, which... More
Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c
August 13, 2015 7:32 AM EDTEleven Biotherapeutics (NASDAQ: EBIO) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $114 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
... More